



# t:slim X2™

Insulin Pump

## Updating to the t:slim X2™ with Basal-IQ™ Technology >

Introducing the NEW remote feature update for the t:slim X2 insulin pump - Basal-IQ technology. Now compatible with Dexcom G6 CGM which is indicated for making treatment decisions with zero fingerpricks and no calibrations<sup>◇</sup>.

The Basal-IQ feature helps reduce the frequency and duration of low-glucose events by predicting low glucose levels 30 minutes ahead and suspends insulin if required.

Key Update Differences		
	t:slim X2 with Basal-IQ Technology* 	t:slim X2 with Dexcom G5 Mobile† Integration 
Basal-IQ Insulin Suspend/Resume Technology	Yes	No
Dexcom CGM Compatibility	Dexcom G6† only	Dexcom G5 Mobile only
Userface	Large, colour touchscreen with NEW menu structure	Large, colour touchscreen
Security Pin	Yes	No
Requires Fingerpricks	Zero fingerpricks required when using Dexcom G6	Calibration and fingerpricks required when using Dexcom G5 Mobile

### How to update your existing t:slim X2‡ to Basal-IQ technology:

- 1 Complete the Software Update Form<sup>A</sup> with your healthcare professional
- 2 Complete the online training module. Once completed, send your training certificate to [diabetes@amsl.com.au](mailto:diabetes@amsl.com.au)
- 3 You will receive a personal update ID and further instructions<sup>§</sup>
- 4 Complete your software update from your personal computer

Always read the label and use only as directed. Read the warnings available on [amsl diabetes.com.au/resources](http://amsl diabetes.com.au/resources) before purchasing. Consult your healthcare professional to see which product is right for you.

For more information on Basal-IQ technology for the t:slim X2 insulin pump, please contact us on **1300 851 056** or at [diabetes@amsl.com.au](mailto:diabetes@amsl.com.au)

[amsl diabetes.com.au](http://amsl diabetes.com.au)    



Once updated, your pump will no longer be compatible with the Dexcom G5 Mobile CGM system and the software update cannot be reversed. <sup>◇</sup>If your glucose alerts and readings from Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions. <sup>\*</sup>Interface and features vary depending on the t:slim X2 insulin pump software version you are using. A full list of features can be found in the respective user guides here [amsl diabetes.com.au/resources](http://amsl diabetes.com.au/resources). <sup>†</sup>Dexcom G5 Mobile and Dexcom G6 sold separately. <sup>‡</sup>Software update available to in-warranty customers only. <sup>§</sup>Software Update Form available from [amsl diabetes.com.au/resources](http://amsl diabetes.com.au/resources). <sup>¶</sup>Please allow up to 3 weeks to receive your update code after submitting all required documentation. The t:slim X2 insulin pump is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin for individuals 6 years of age or greater. The t:slim X2 insulin pump can be used solely for continuous insulin delivery and/or as part of the t:slim X2 system to receive and display continuous glucose measurements from the Dexcom G5 Mobile or Dexcom G6 (dependent on the software version being used). The t:slim X2 system also includes continuous glucose monitoring (CGM) indicated for the management of diabetes. Interpretation of the t:slim X2 system results should be based on the trends and patterns seen with several sequential readings over time. The device is indicated for use with U-100 fast-acting insulin. **Responsible use of Basal-IQ technology:** Systems like the t:slim X2 insulin pump with Basal-IQ technology are not substitutes for the active management of diabetes. There are common scenarios in which automated systems cannot prevent a hypoglycaemic event. It's recommended users always use the components of the pump system (pump, cartridges, CGM, and infusion sets) according to the applicable instructions for use and check them regularly to make sure they are functioning as expected. Users should always pay attention to their symptoms, actively monitor and manage glucose levels and treat according to their healthcare professionals' recommendations. For detailed indications for use and safety information, call AMSL Diabetes on 1300 851 056 or visit [amsl diabetes.com.au](http://amsl diabetes.com.au) © 2020 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc. Dexcom G5 Mobile and Dexcom G6 is a registered trademark of Dexcom, Inc. **References:** 1. Forlenza GP, Li Z, Buckingham BA, et al. Predictive low glucose suspend reduces hypoglycemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial. Diabetes Care. 2018;41(10):2155-2161 **ARTG 304681. PR-100-418 August 2020**